Research

Hormonal

Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.

Unlike insulin, Tirzepatide does not increase the risk of low blood sugar (hypoglycemia) when used alone. In fact, it has a lower risk of causing hypoglycemia compared to basal insulin. This makes it a safer option for patients who are concerned about blood sugar lows.

StrongRefutesHIGH confidence
Incidence of hypoglycaemia with tirzepatide was similar vs placebo and lower vs basal insulin.
Thomas Karagiannis et al. · Diabetologia · 2022

Why this rating

Meta-analysis of 7 RCTs.

Source

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Thomas Karagiannis et al. · Diabetologia · 2022

DOI 10.1007/s00125-022-05715-4

Meta-analysis · 7 studiesCited 256×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →